Peptide therapy for increasing platelet levels

A technique for counting platelets and platelets, which is applied to tripeptide components, blood diseases, peptide/protein components, etc., and can solve problems such as not being disclosed or revealed
CN102481332AInactive Publication Date: 2012-05-30BIOKINE THERAPEUTICS LTD
14 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BIOKINE THERAPEUTICS LTD
Publication Date
2012-05-30
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to compositions and methods for modulating platelet levels. Background technique

[0002] Platelets, also known as thrombus cells, are anucleated cell fragments present in mammalian blood that mediate clot formation and hemostasis. In addition, platelets release growth factors that play an important role in the repair and regeneration of connective tissue and can promote wound healing. Platelets are the final differentiation products of megakaryocytes (MK), which in turn originate from pluripotent stem cells of the bone marrow. Although humoral factors such as thrombopoietin (TPO) were found to affect different cellular steps of megakaryocyte development, the complex mutation, differentiation, and localization processes that begin with pluripotent stem cells and end with platelets are not fully understood.

[0003] The average lifespan of platelets is about 5 to 10 days, and their physiological blood levels are normally ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More